Janssen Global Public Health and the Stop TB Partnership's Global Drug Facility to collaborate on the global introduction of Bedaquiline (Sirturo)

Posted by Mutaleni on May 7, 2014

Dear partners, 

We share with you great news in terms of new drugs and better diagnostics for multi-drug resistant Tuberculosis (MDR-TB). 

ARASA, along with other strategic partners such as the Treatment Action Group (TAG) have been advocating for the expeditious accessibility of this new drug, bedaquiline (clinical trial TMC207) since 2012. Bedaquiline is a Janssen-developed drug indicated for use as part of combination therapy to treat adults with multi-resistant tuberculosis (MDR-TB).

ARASA, MSF, Treatment Action Campaign (TAC) and SECTION27, in South Africa, advocated for the "compassionate use" of the drug in South Africa. This did not receive approval from the Medicines Control Council (MCC), as it was in its last stages of clinical trials in early 2013. 

Please see news from the Global Drug Facility (GDF). The drug, bedaquiline (Sirturo) is now available for procurement through the Stop TB Partnership’s Global Drug Facility and its procurement agent, the International Dispensary Association (IDA).  The price and marketing strategy relating to bedaquiline have been defined and set by the manufacturer, who is the sole source supplier of this product to date.  

We should advocate for our government to get their procurement agencies to get onto this drug into the public sector. Activist guide to Bedaquiline

Thank you